Cargando…
Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims
Medicaid formulary committees and other gatekeepers face a difficult task. On the one hand they can utilize technical expertise in evaluating the real world evidence for clinical, quality of life and resource utilization claims for competing products while on the other hand they may be asked to asse...
Autor principal: | Langley, Paul C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102970/ https://www.ncbi.nlm.nih.gov/pubmed/34007677 http://dx.doi.org/10.24926/iip.v12i1.3702 |
Ejemplares similares
-
CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)
por: Langley, Paul C
Publicado: (2018) -
Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare Disease
por: Langley, Paul C
Publicado: (2022) -
Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review
por: Langley, Paul C
Publicado: (2021) -
The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies
por: Langley, Paul C
Publicado: (2019) -
The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment
por: Langley, Paul C
Publicado: (2020)